Details for New Drug Application (NDA): 211840
✉ Email this page to a colleague
NDA 211840 describes LISDEXAMFETAMINE DIMESYLATE, which is a drug marketed by Actavis Elizabeth, Alkem Labs Ltd, Amneal, Apotex, Ascent Pharms Inc, Elite Labs Inc, Granules, Hikma, Lannett Co Inc, Mylan, Norwich, Prinston Inc, Rhodes Pharms, Sandoz, Specgx Llc, Sun Pharm Inds Inc, MSN, and Teva Pharms, and is included in twenty-two NDAs. It is available from nineteen suppliers. Additional details are available on the LISDEXAMFETAMINE DIMESYLATE profile page.
The generic ingredient in LISDEXAMFETAMINE DIMESYLATE is lisdexamfetamine dimesylate. Twenty suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.
The generic ingredient in LISDEXAMFETAMINE DIMESYLATE is lisdexamfetamine dimesylate. Twenty suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.
Summary for 211840
| Tradename: | LISDEXAMFETAMINE DIMESYLATE |
| Applicant: | Specgx Llc |
| Ingredient: | lisdexamfetamine dimesylate |
| Patents: | 0 |
Pharmacology for NDA: 211840
| Physiological Effect | Central Nervous System Stimulation |
Medical Subject Heading (MeSH) Categories for 211840
Suppliers and Packaging for NDA: 211840
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LISDEXAMFETAMINE DIMESYLATE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 211840 | ANDA | SpecGx LLC | 0406-5111 | 0406-5111-01 | 100 CAPSULE in 1 BOTTLE (0406-5111-01) |
| LISDEXAMFETAMINE DIMESYLATE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 211840 | ANDA | SpecGx LLC | 0406-5112 | 0406-5112-01 | 100 CAPSULE in 1 BOTTLE (0406-5112-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 10MG | ||||
| Approval Date: | Aug 25, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 20MG | ||||
| Approval Date: | Aug 25, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 30MG | ||||
| Approval Date: | Aug 25, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
